Live price temporarily unavailable.
Nautilus Biotechnology (NAUT) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Net income | −$15.6M | −$50.3M | −$57.9M | −$63.7M | −$70.8M | −$59.0M |
| EPS (diluted) | −$0.54 | −$0.60 | −$0.46 | −$0.51 | −$0.56 | −$0.47 |
| Balance sheet | ||||||
| Cash and equivalents | $36.6M | $185.6M | $114.5M | $19.4M | $27.6M | $12.4M |
| Total assets | $85.0M | $398.4M | $350.1M | $305.6M | $242.7M | $191.1M |
| Total liabilities | $6.31M | $34.9M | $35.1M | $40.2M | $34.0M | $34.1M |
| Shareholders' equity | −$29.7M | $363.6M | $314.9M | $265.4M | $208.7M | $157.0M |
| Cash flow | ||||||
| Operating cash flow | −$14.0M | −$39.2M | −$45.8M | −$51.7M | −$59.1M | −$50.7M |
| Capital expenditure | $921.0K | $2.27M | $2.32M | $2.44M | $2.12M | $1.28M |
| Free cash flow | −$14.9M | −$41.5M | −$48.1M | −$54.2M | −$61.3M | −$52.0M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25†Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26†Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | $0 | $0 | — | — | $0 | $190.0K |
| Gross profit | — | — | $0 | $0 | — | — | $0 | $175.0K |
| Gross margin | — | — | — | — | — | — | — | 92.1% |
| Net income | −$16.4M | −$17.6M | −$16.6M | −$15.0M | −$13.6M | −$13.8M | −$14.7M | −$14.5M |
| Net margin | — | — | — | — | — | — | — | −7615.3% |
| EPS (diluted) | −$0.13 | −$0.14 | −$0.13 | −$0.12 | −$0.11 | −$0.11 | −$0.12 | −$0.11 |
| Balance sheet | ||||||||
| Cash and equivalents | $4.41M | $27.6M | $33.2M | $34.5M | $23.9M | $12.4M | $14.6M | $13.2M |
| Total assets | $259.7M | $242.7M | $227.7M | $213.2M | $200.9M | $191.1M | $177.8M | $163.6M |
| Total liabilities | $36.3M | $34.0M | $33.3M | $32.1M | $31.8M | $34.1M | $33.4M | $32.5M |
| Shareholders' equity | $223.4M | $208.7M | $194.4M | $181.1M | $169.1M | $157.0M | $144.4M | $131.1M |
| Cash flow | ||||||||
| Operating cash flow | −$13.1M | −$14.3M | −$13.9M | −$13.3M | −$11.0M | −$12.4M | −$13.1M | −$13.7M |
| Capital expenditure | $709.0K | $254.0K | $219.0K | $396.0K | $418.0K | $244.0K | $510.0K | $454.0K |
| Free cash flow | −$13.8M | −$14.6M | −$14.2M | −$13.7M | −$11.5M | −$12.6M | −$13.6M | −$14.2M |
From Nautilus Biotechnology's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Nautilus Biotechnology in our feed yet.